The Marshall Protocol Study Site Home




Search by username
   Not logged in - Login | Register 

Generic versions of Benicar
 Moderated by: Prof Trevor Marshall
Topic closed

New Topic

Prof Trevor Marshall
Foundation Staff

Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 16174
Status:  Offline
 Posted: Wed Jan 13th, 2016 21:29
Sankyo's patent on Olmesartan Medoxomil expires on October 25th. Mylan has a generic version approved by the FDA, but it appears Mylan has done some sort of deal with Sankyo. It is common in the pharmaceutical industry for a manufacturer to seek to maintain its income stream by making deals which will maintain the current pricing, even after the drug has gone generic.

Mylan had a 6 month exclusivity (starting on Oct 25) to sell the generic product. But they have been challenged by Apotex, and a judge has just ruled in Apotex's favor:

Maintaining the high price must be a big deal for Sankyo, as they sold $2.4 Billion of Olmesartan Internationally in 2014.

As you can see from the article, the legal jostling is complex, and primarily based on loopholes in the law and FDA regulations. But hopefully there will be three players in the market starting October 25. Just don't expect a precipitate drop in pricing. PhRMA doesn't work that way :)

 Current time is 03:52

* We can help you understand chronic disease, but only your physician is licensed to give you medical care *

Powered by WowBB 1.7 - Entire site Copyright © 2004-2020 Autoimmunity Research Foundation, All Rights Reserved
Click here to view our PRIVACY POLICY
Page processed in 0.3212 seconds (98% database + 2% PHP). 18 queries executed.